Silo Pharma, Inc. (SILO)
| Market Cap | 5.35M |
| Revenue (ttm) | 72,102 |
| Net Income (ttm) | -3.70M |
| Shares Out | 2.84M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 385,082 |
| Open | 1.630 |
| Previous Close | 1.780 |
| Day's Range | 1.630 - 1.950 |
| 52-Week Range | 1.216 - 3.050 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+431.92%) |
| Earnings Date | n/a |
About SILO
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company ... [Read more]
Financial Performance
In 2023, Silo Pharma's revenue was $72,102, a change of 0.00% compared to the previous year's $72,102. Losses were -$3.70 million, -5.32% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for SILO stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a de...
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental...
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmenta...
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: ...
Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharm...
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01, 2024 (GLO...
Silo Pharma Announces Positive Results in Alzheimer's Disease Study
Preclinical study shows SPC-14's effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Si...
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biophar...
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”)...
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia ENGLEWO...
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-i...
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developm...
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), ...
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”...
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
Investigational New Drug (IND) submission to FDA on target for Q1 2024
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
Clarivate will monitor, manage, and maintain Company's expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental...
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / June 23, 2023 / This month, Silo Pharma (NASDAQ:SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromya...
Silo Pharma's SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
New patent expands Company's intellectual property and technology rights portfolio New patent expands Company's intellectual property and technology rights portfolio
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical ...
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
Webull's investor community can now access the SILO profile for real-time data and investor communications ENGLEWOOD CLIFFS, NJ, June 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“th...
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
Phase 2 of study will further investigate the peptides' method, optimization, and binding affinity in human tissue
Silo Pharma's SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer's Disease
ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics wi...
Silo Pharma to Present at Psychedelic Drug Development Conference
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
SPU-26 Pain Management Using Ketamine Composition
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...